Impact of age, sex, physical function, health-related quality of life, and treatment with adalimumab on work status and work productivity of patients with ankylosing spondylitis

Journal of Rheumatology

Volumn 37, Issue 2, 2010, Pages 385-392

  Maksymowych, Walter P ^a   Gooch, Katherine L ^b   Wong, Robert L ^b   Kupper, Hartmut ^c   Van Der Heijde, Désirée ^d  

^a UNIVERSITY OF ALBERTA   (Canada)

^b ABBOTT LABORATORIES   (United States)

^c ABBOTT GMBH AND CO KG   (Germany)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Adalimumab; Ankylosing spondylitis; Employment status; Health related quality of life; Patient reported outcomes; Work productivity

Indexed keywords

ADALIMUMAB;

ABSENTEEISM; ADULT; AGE DISTRIBUTION; ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; FEMALE; HUMAN; HYPOTHESIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; OUTCOME ASSESSMENT; PAIN; PHYSICAL CAPACITY; PRIORITY JOURNAL; PRODUCTIVITY; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SEX DIFFERENCE; SHORT FORM 36; WORK CAPACITY;

ABSENTEEISM; ACTIVITIES OF DAILY LIVING; ADULT; AGE FACTORS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; DISABILITY EVALUATION; DOUBLE-BLIND METHOD; EFFICIENCY; EMPLOYMENT; FEMALE; HEALTH STATUS; HEALTH SURVEYS; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME;

EID: 76649129836     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.090242     Document Type: Article

References (39)

1. Boonen A, van der Linden SM. The burden of ankylosing spondylitis. J Rheumatol 2006;33 Suppl 78:4-11.
2. Dagfinrud H, Mengshoel AM, Hagen KB, Loge JH, Kvien TK. Health status of patients with ankylosing spondylitis: a comparison with the general population. Ann Rheum Dis 2004;63:1605-10.
3. Akkoc N, Khan MA. Overestimation of the prevalence of ankylosing spondylitis in the Berlin study: comment on the article by Braun et al. Arthritis Rheum 2005;52:4048-9.
4. Braun J, Bollow M, Remlinger G, Eggens U, Rudwaleit M, Distler A, et al. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 1998;41:58-67.
5. Ward MM. Functional disability predicts total costs in patients with ankylosing spondylitis. Arthritis Rheum 2002;46:223-31.
6. Boonen A, van der Heijde D, Landewe R, Spoorenberg A, Schouten H, Rutten-van Mölken M, et al. Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries. Ann Rheum Dis 2002;61:429-37.
7. McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, et al. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation. Health Technol Assess 2007;11:1-158.
8. Boonen A. Socioeconomic consequences of ankylosing spondylitis. Clin Exp Rheumatol 2002;20 Suppl 28:S23-6.
9. Boonen A, Chorus A, Miedema A, van der Heijde D, Landewé R, Schouten H, et al. Withdrawal from labour force due to work disability in patients with ankylosing spondylitis. Ann Rheum Dis 2001;60:1033-9.
10. Koopman C, Pelletier KR, Murray JF, Sharda CE, Berger ML, Turpin RS, et al. Stanford presenteeism scale: health status and employee productivity. J Occup Environ Med 2002;44:14-20.
11. Mattke S, Balakrishnan A, Bergamo G, Newberry SJ. A review of methods to measure health-related productivity loss. Am J Manag Care 2007;13:211-7.
12. Stewart WF, Ricci JA, Chee E, Morganstein D, Lipton R. Lost productive time and cost due to common pain conditions in the US workforce. JAMA 2003;290:2443-54.
13. Schultz AB, Edington DW. Employee health and presenteeism: a systematic review. J Occup Rehabil 2007;17:547-79.
14. van der Heijde D, Han C, DeVlam K, Burmester G, van den Bosch F, Williamson P, et al. Infliximab improves productivity and reduces workday loss in patients with ankylosing spondylitis: results from a randomized placebo-controlled trial. Arthritis Rheum 2006;55:569-74.
15. Boonen A, Severens JL. Ankylosing spondylitis: what is the cost to society, and can it be reduced? Best Pract Res Clin Rheumatol 2002;16:691-705.
16. Braun J, McHugh N, Singh A, Wajdula JS, Sato R. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly. Rheumatology 2007;46:999-1004.
17. Davis JC Jr, van der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003;48:3230-6.
18. van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis. Arthritis Rheum 2006;54:2136-46.
19. Davis JC, van der Heijde D, Dougados M, Woolley JM. Reductions in health-related quality of life in patients with ankylosing spondylitis and improvements with etanercept therapy. Arthritis Rheum 2005;53:494-501.
20. Davis JC Jr, Revicki D, van der Heijde DM, Rentz AM, Wong RL, Kupper H, et al. Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: results from a randomized controlled study. Arthritis Rheum 2007;57:1050-7.
21. van der Heijde D, Pangan AL, Schiff MH, Braun J, Borofsky M, Torre J, et al. Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis. Ann Rheum Dis 2008;67:1218-21.
22. van der Heijde D, Schiff MH, Sieper J, Kivitz A, Wong RL, Kupper H, et al. Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Ann Rheum Dis 2009;68:922-9.
23. Haywood KL, Garratt AM, Jordan K, Dziedzic K, Dawes PT. Disease-specific, patient-assessed measures of health outcome in ankylosing spondylitis: reliability, validity and responsiveness. Rheumatology 2002;41:1295-302.
24. Prasad M, Wahlqvist P, Shikiar R, Shih YC. A review of self-report instruments measuring health-related work productivity: a patient-reported outcomes perspective. Pharmacoeconomics 2004;22:225-44.
25. Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 Health survey manual and interpretation guide. Boston: New England Medical Center, The Health Institute, 1993.
26. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
27. Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21:2281-5.
28. Doward LC, Spoorenberg A, Cook SA, Whalley D, Helliwell PS, Kay LJ, et al. The Development of the ASQOL: A quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis 2003;62:20-6.
29. Furlong WJ, Feeny DH, Torrance GW, Barr RD. The Health Utilities Index (HUI) system for assessing health-related quality of life in clinical studies. Ann Med 2001;33:375-84.
30. Reilly MC, Gerlier L, Brabant Y, Brown M. Validity, reliability, and responsiveness of the work productivity and activity impairment questionnaire in Crohn's disease. Clin Ther 2008;30:393-404.
31. Clark DO, Von Korff M, Saunders K, Baluch WM, Simon GE. A chronic disease score with empirically derived weights. Med Care 1995;33:783-95.
32. Kennedy LG, Jenkinson TR, Mallorie PA, Whitelock HC, Garrett SL, Calin A. Ankylosing spondylitis: the correlation between a new metrology score and radiology. Br J Rheumatol 1995;34:767-70.
33. van der Heijde DM, Revicki DA, Gooch KL, Wong RL, Kupper H, Harnam N, et al, for the ATLAS Study Group. Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis. Arthritis Res Ther 2009,11:R124(doi:10. 1186/ar2790).
34. Keat AC, Gaffney K, Gilbert AK, Harris C, Leeder J. Influence of biologic therapy on return to work in people with work disability due to ankylosing spondylitis. Rheumatology 2008;47:481-3.
35. Listing J, Brandt J, Rudwaleit M, Zink A, Sieper J, Braun J. Impact of anti-tumour necrosis factor treatment on admissions to hospital and days of sick leave in patients with ankylosing spondylitis. Ann Rheum Dis 2004;63:1670-2.
36. Boonen A. A review of work-participation, cost-of-illness and cost-effectiveness studies in ankylosing spondylitis. Nat Clin Pract Rheumatol 2006;2:546-53.
37. Kivimäki M, Vahtera J, Thomson L, Griffiths A. Psychosocial factors predicting employee sickness absence during economic decline. J Appl Psychol 1997;82:858-72.
38. van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005;52:582-91.
39. Sailly JC, Lebrun T. Les conséquences économiques et sociales de la pelvispondylite rhumatismale. Rev Epidemiol Santé Publique 1982;30:305-24.